98 related articles for article (PubMed ID: 1601678)
41. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
McMillan GP; Konrad-Martin D; Dille MF
Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
[TBL] [Abstract][Full Text] [Related]
42. [Electrophysiological evaluation of the hearing function following cisplatin administration].
Bogomol'skiĭ MR; D'iakonova IN; Rakhmanova IV; Sapozhnikov IaM; Stakhovskaia OR; Tikhomirov AM
Vestn Otorinolaringol; 2010; (3):24-6. PubMed ID: 20559247
[TBL] [Abstract][Full Text] [Related]
43. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy.
Zorowka PG; Schmitt HJ; Gutjahr P
Int J Pediatr Otorhinolaryngol; 1993 Jan; 25(1-3):73-80. PubMed ID: 8436482
[TBL] [Abstract][Full Text] [Related]
44. [Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy].
Hyppolito MA; de Oliveira AA; Lessa RM; Rossato M
Braz J Otorhinolaryngol; 2005; 71(3):268-73. PubMed ID: 16446928
[TBL] [Abstract][Full Text] [Related]
45. N1 latency prolongation in the guinea pig cochlea treated with nitrogen mustard-N-oxide studied by narrow band analysis.
Ikeda K; Kusakari J; Kawamoto K
Ann Otol Rhinol Laryngol; 1987; 96(2 Pt 1):182-6. PubMed ID: 3105408
[TBL] [Abstract][Full Text] [Related]
46. [Evaluation of cochlear function by means of otoacoustic emission in children treated with cytostatic drugs in the course of bone marrow proliferative diseases].
Namysłowski G; Trybalska G; Morawski K; Scierski W; Urbaniec P; Sońta-Jakimczyk D; Janik-Moszant A
Otolaryngol Pol; 2000; 54(6):769-74. PubMed ID: 11265390
[TBL] [Abstract][Full Text] [Related]
47. [Study of the ototoxicity of amikacin and netilmicin using provoked acoustic oto-emissions and high-frequency audiometry].
Collet L; Veuillet E; Chanal JM; Desreux V; Mermet B; Disant F; Morgon A
Pathol Biol (Paris); 1992 Dec; 40(10):990-2. PubMed ID: 1299814
[TBL] [Abstract][Full Text] [Related]
48. Ototoxicity of kanamycin in developing rats: relationship with the onset of the auditory function.
Marot M; Uziel A; Romand R
Hear Res; 1980 Mar; 2(2):111-3. PubMed ID: 7364666
[TBL] [Abstract][Full Text] [Related]
49. Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate.
Yıldırım M; Inançlı HM; Samancı B; Oktay MF; Enöz M; Topçu I
Kulak Burun Bogaz Ihtis Derg; 2010; 20(4):173-83. PubMed ID: 20626325
[TBL] [Abstract][Full Text] [Related]
50. Another response to the article "Comparison of pure tone audiometry thresholds and transient evoked otoacoustic emissions (TEOAE) in patients with and without Covid-19 pneumonia".
Aksit AM
Am J Otolaryngol; 2023; 44(1):103664. PubMed ID: 36323156
[No Abstract] [Full Text] [Related]
51. Audiological profile and cochlear functionality in Williams syndrome.
Silva LAF; Kawahira RSH; Kim CA; Matas CG
Codas; 2022; 34(3):e20210041. PubMed ID: 35043861
[TBL] [Abstract][Full Text] [Related]
52. Are aminosugars ototoxic?
Tachibana M; Jung W; Schindler K; Schacht J
Arch Otorhinolaryngol; 1981; 230(2):103-7. PubMed ID: 7295169
[TBL] [Abstract][Full Text] [Related]
53. [Relation of evoked otoacoustic emission to structural damage after acoustic overstimulation in cat].
Iwasaki S
Nihon Jibiinkoka Gakkai Kaiho; 1993 Apr; 96(4):637-44. PubMed ID: 8509937
[TBL] [Abstract][Full Text] [Related]
54. Time-frequency analysis of transient-evoked otoacoustic emissions in children exposed to carboplatin chemotherapy.
Bhagat S; Bass J; Qaddoumi I; Brennan R; Wilson M; Wu J; Galindo CR; Paglialonga A; Tognola G
Audiol Neurootol; 2013; 18(2):71-82. PubMed ID: 23147804
[TBL] [Abstract][Full Text] [Related]
55. Detection of early ototoxic effect in testicular-cancer patients treated with cisplatin by transiently evoked otoacoustic emission: a pilot study.
Biró K; Baki M; Büki B; Noszek L; Jókúti L
Oncology; 1997; 54(5):387-90. PubMed ID: 9260600
[TBL] [Abstract][Full Text] [Related]
56. Electrocochleography during intravenous infusion of cisplatin.
Yung MW; Dorman EB
Arch Otolaryngol Head Neck Surg; 1986 Aug; 112(8):823-6. PubMed ID: 3718685
[TBL] [Abstract][Full Text] [Related]
57. Role of Otoacoustic Emission in Early Detection of Cisplatin Induced Ototoxicity.
Shetty S; Bhandary SK; Bhat V; Aroor R; Shetty J; Dattatreya T
Indian J Otolaryngol Head Neck Surg; 2022 Aug; 74(Suppl 1):164-169. PubMed ID: 36032922
[TBL] [Abstract][Full Text] [Related]
58. Application of a neuroprotective ACTH(4-9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs.
Hamers FP; Klis SF; Gispen WH; Smoorenburg GF
Eur Arch Otorhinolaryngol; 1994; 251(1):23-9. PubMed ID: 8179863
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of Risk Factors Causing Ototoxicity in Childhood Cancers Located in the Head and Neck Region Treated With Platinum-based Chemotherapy.
Olgun Y; Çakir Kizmazoğlu D; İnce D; Ellidokuz H; Güneri EA; Olgun N; Kirkim G
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e930-e934. PubMed ID: 33885038
[TBL] [Abstract][Full Text] [Related]
60. The effect of furosemide on evoked otoacoustic emissions in guinea pigs.
Ueda H; Hattori T; Sawaki M; Niwa H; Yanagita N
Hear Res; 1992 Oct; 62(2):199-205. PubMed ID: 1429263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
